Calavo Growers, Inc. reported financial results for the third fiscal quarter and nine-month period ended July 31, 2025. In the third quarter, total net sales were $178.8 million, with fresh segment sales at $155.9 million (5% decrease) and prepared segment sales at $22.9 million (40% increase). Gross profit was $18.2 million, with $4.2 million in discrete costs due to a temporary FDA detention hold. Net income from continuing operations was $4.7 million. For the nine-month period, total net sales were $523.8 million, with fresh segment sales at $470.3 million (6% increase) and prepared segment sales at $53.5 million (10% increase). Gross profit was $52.0 million. Adjusted net income was $23.8 million. The company ended the quarter with $63.8 million in cash and $114.3 million in available liquidity. Non-GAAP financial measures include adjusted EBITDA and adjusted net income. Management highlighted challenges and opportunities, including a temporary FDA detention hold and growth in the Prepared segment. The company is pursuing recovery from insurance for FDA detention hold costs. Forward-looking statements were provided with associated risks. Total assets were $301.2 million, with total liabilities at $93.2 million and shareholders' equity at $208 million. Contact for investors: Jeremy Apple, Senior Vice President at Financial Profiles, Inc. 310-622-8233. The full story is available on Benzinga.com.